Image source: The Motley Fool.

DATE

Thursday, Nov. 6, 2025 at 4:30 p.m. ET

CALL PARTICIPANTS

• President and Chief Executive Officer — Dr. David J. Mazzo
• Executive Vice President of Research and Development and Chief Medical Officer — Dr. Kristen K. Buck
• Senior Vice President of Finance and Treasury and Chief Accounting Officer — James Nisco

Need a quote from a Motley Fool analyst? Email [email protected]

TAKEAWAYS

• Operating Expenses – $4.4 million, down $900,000 or 17.3% compared to $5.3 million for the same period in the prior year, due primarily to reduced R&D and general administrative spending.
• Research and Development Expenses – $2 million, a $600,000 or 22.9% decrease from $2.5 million in the comparable quarter, attributed to lower chemistry, manufacturing, and controls costs and reduced clinical department spend, partially offset by increased BOLTAR trial costs due to a prior year CRO refund.
• General and Administrative Expenses – $2.5 million, a decrease of $300,000 or 12.1% from $2.8 million for the same quarter last year, mainly due to lower consulting costs and elimination of a position.
• Net Loss – $4.2 million, reduced from $4.9 million for the corresponding period last year.
• Cash and Cash Equivalents – $19 million as of quarter-end, with management projecting a runway into 2027 for current operations and clinical activities, excluding expenditure for a Phase III ASCEND trial.
• ASCEND Trial Development – Preliminary Cohort B data exhibited a positive trend in progression-free survival, overall survival, and objective response rate for cerdepatide plus standard of care compared to placebo; a complete response was observed only in the treatment group.
• ASCEND Safety – Pooled analysis from both cohorts A and B indicated “no increased adverse events in the cerdepatide plus standard of care treated group beyond those experienced in the standard of care plus placebo-treated groups.”
• ASCEND Regulatory Progress – A completed end-of-Phase II meeting with FDA led to agreement on “the fundamental aspects of an acceptable global Phase III protocol including dose and dosing regimen, blinding, and primary endpoints.” Management confirmed readiness for Phase III subject to available capital.
• BOLTAR Trial Update – Enrollment for the first-line cholangiocarcinoma arm finished nearly six months ahead of plan; total enrollment in the second-line cohort was capped at 20 patients for efficiency, with this exploratory arm not statistically powered.
• SENDFOX Trial Data – Preliminary results in the pancreatic cancer cohort showed a 50% R0 resection rate and a 70% pathological partial response among patients completing therapy, with a reported 60% two-year overall survival rate.
• IELISTA Trial Status – Enrollment is complete, and interim analysis revealed “compelling positive preliminary data” for cerdepatide in combination with immunotherapy, with final outcomes expected in 2026.
• GBM Trial Progress – Enrollment is approximately two-thirds complete toward the 30-patient target, proceeding on schedule.
• Chilu Licensee Update – Development partner Chilu completed patient enrollment (90 subjects) in metastatic pancreatic cancer; initial data is anticipated in the next 12 to 18 months.
• Catalent Licensing Agreement – A nonexclusive global license was granted to Catalent (NYSE:CTLT) for use of cerdepatide and its analogs as payloads for the SmartTag ADC platform; Catalent’s preclinical results demonstrated enhanced tumor-selective penetration and efficacy.
• Strategic Alliance with GATC Health – Entered a collaboration to leverage AI-powered drug discovery for new indications and novel compounds, with several candidates targeted for clinical development in 2026.
• Patent Extension – The U.S. Patent and Trademark Office issued a new composition of matter patent for cerdepatide in July 2025, providing protection through March 2040 with potential extensibility.

SUMMARY

Lisata Therapeutics (NASDAQ:LSTA) reported material progress in both clinical and corporate initiatives, including a pronounced reduction in operating expenditures and strengthened capital position. Management advanced multiple cerdepatide clinical programs with new trial data indicating clinical benefit and maintained positive safety profiles across diverse oncology indications. Strategic alliances with Catalent and GATC Health, as well as an extended patent estate, reinforce near-term opportunities for product, platform, and non-dilutive capital expansion. The company articulated a clear regulatory and operational pathway for a Phase III ASCEND trial, though noted this is contingent on securing additional funding, with management actively seeking partnering solutions.

• The financial runway extends into 2027, but no Phase III ASCEND expenditures are included in this projection, as acknowledged by management.
• Management said, “The original trial was designed with an academic bench rather than one with commercial and regulatory objectives and was statistically powered based on a six-month progression-free survival primary endpoint. This endpoint is unusual in that it has not been previously used as the basis of approval for an anticancer drug.”
• Lisata’s leadership emphasized direct engagement with potential licensing partners, citing recent Catalent and Chilu agreements as cornerstones for continued business development efforts.
• Dr. Mazzo clarified that “in this current financing environment, it’s going to be next to impossible to raise the amount of money necessary to unilaterally fund that phase three in a manner that would not be so overly dilutive to current shareholders,” underscoring reliance on strategic investment or partnering to execute next-phase trials.
• Several ongoing and near-readout investigator-initiated studies may introduce future variability in timelines, with final ASCEND, IELISTA, and Chilu metastatic pancreatic cancer study data all targeted for 2026 or beyond.

INDUSTRY GLOSSARY

• CD34+ cell therapy: A regenerative treatment utilizing hematopoietic stem cells expressing the CD34 marker, aimed at tissue repair and disease reversal.
• CRO (Contract Research Organization): An external service provider managing clinical trial operations, data management, and protocol execution.
• R0 resection: Surgical removal of a tumor with negative margins, indicating no microscopic residual cancer at the cut edge.
• RECIST (Response Evaluation Criteria in Solid Tumors): A standardized measurement framework for tumor response in clinical trials, based on changes in tumor size.
• SmartTag ADC (Antibody-Drug Conjugate): Catalent’s targeted drug platform enabling tissue-selective delivery of cytotoxic agents via engineered antibodies tagged with customizable payloads.
• PD-1/PD-L1: Immune checkpoint proteins targeted by immunotherapies to enhance anti-tumor immune responses.

Full Conference Call Transcript

Dr. David Mazzo, President and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer. Shortly before this call, we issued a press release announcing our third quarter 2025 financial results, which is available under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received the news release or if you would like to be added to the company’s email distribution list, please subscribe to the email alerts on the company website or email me at [email protected] to be added. Sorry.

Before we begin, I remind you that comments made by management during this conference call contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lisata Therapeutics. I encourage you to review the company’s filings with the Securities and Exchange Commission, including without limitation, its Forms 10-Q, 8-Ks, and 10-Ks, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, November 6, 2025.

Lisata Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I will now turn the call over to Dr. David Mazzo. Dave?

David Mazzo: Thank you, John, and good afternoon, everyone. It’s my pleasure to provide the latest update of Lisata Therapeutics’ recent business highlights, discuss our third quarter 2025 financial results, and give a report on the progress of our development programs. Building on the momentum from the first half of the year, Lisata Therapeutics achieved several development milestones involving cerdepatide, including the announcement of encouraging preliminary results from multiple studies including the ASCEND trial, the IELISTA trial, and the SENDFOX trial, adding further corroboration to our expectations of the positive impact of cerdepatide as part of various anticancer treatment regimens.

On the business development front, we entered into a strategic alliance with GATC Health to use their multinomial Advanced Technology Artificial Intelligence Drug Discovery platform to identify product candidates for development. We also executed a nonexclusive global license agreement with Catalent in which Catalent gains access to cerdepatide and its analogs for use as a payload for their SmartTag ADC technology platform. We continue to anticipate that the next several quarters will be a data and transaction-rich period for Lisata Therapeutics with several key milestones on the horizon. Following the review of our financial results, Dr.

Kristen Buck, our Chief Medical Officer and Head of R&D, will provide an update on our ongoing and planned clinical studies, including timelines and key achievements. With that, I will now turn the call over to James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer. James?

James Nisco: Thanks, Dave. Good afternoon, I’m pleased to join you today to present a summary of our third quarter 2025 financial results. Next, a review of our operating expenses. For the three months ended September 30, 2025, operating expenses totaled $4.4 million compared to $5.3 million for the three months ended September 30, 2024, representing a decrease of $900,000 or 17.3%. Research and development expenses were approximately $2 million for the three months ended September 30, 2025, compared to $2.5 million for the three months ended September 30, 2024, representing a decrease of $600,000 or 22.9%.

This was primarily due to lower spend on chemistry, manufacturing and controls, and a reduction in clinical department expenses, partially offset by an increase in the bolster trial costs as a result of a CRO refund in the prior year quarter related to trial protocol modifications. On a year-over-year comparison, for the nine months ended September 30, 2025, bolster trial costs are lower than the prior year. General and administrative expenses were approximately $2.5 million for the three months ended September 30, 2025, compared to $2.8 million for the three months ended September 30, 2024, representing a decrease of $300,000 or 12.1%. This was primarily due to lower spend on consulting and savings from the elimination of an employee position.

Overall, net losses were $4.2 million for the three months ended September 30, 2025, compared to $4.9 million for the three months ended September 30, 2024. It is noteworthy that we continue to make progress according to our plans for our R&D and business activities while continuing our legacy of prudent capital management and expense minimization. Turning now to our balance sheet and cash flow. As of September 30, 2025, we had cash and cash equivalents of approximately $19 million. Based on our existing and planned activities, the company projects that available funds will support current operations into 2027. With that, I will now turn the call over to Dr.

Kristen Buck to provide an overview of the company’s development programs.

Kristen Buck: Thank you, James, and good afternoon, everyone. It’s a pleasure to be here today to present an update on our clinical development portfolio, including near-term catalysts. As mentioned on previous quarterly calls, Lisata Therapeutics is focused on the development of its proprietary cyclic internalizing RGD peptide product candidate, cerdepatide, for the treatment of advanced solid tumors and other difficult-to-treat diseases. Cerdepatide is designed to activate a novel uptake pathway that allows co-administered or tethered anticancer drugs to selectively target and penetrate solid tumors more effectively. In addition, cerdepatide has been shown to modify the tumor microenvironment, making it less immunosuppressive and therefore increasing the tumor’s susceptibility to immunotherapy and our body’s own immune system while also inhibiting the metastatic cascade.

If you’d like more information regarding cerdepatide’s mechanism of action, we encourage you to visit our website where you’ll find an animated video and relevant slides within our corporate presentation. On the regulatory front, cerdepatide has secured multiple special designations from both the U.S. FDA and EMA, all of which are also listed on our website and in the corporate presentation for your easy reference. Now for an update on our individual development programs. The ASCEND trial is a Phase 2b 158 patient, double-blind, randomized, placebo-controlled clinical trial evaluating cerdepatide in combination with standard of care gemcitabine and nab-paclitaxel chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma, or M-DAC.

Patient recruitment was conducted at 25 sites in Australia and New Zealand and is sponsored by the Australasian Gastrointestinal Clinical Trials Group or AGITG in collaboration with the National Health and Medical Research Council Clinical Trial Center at the University of Sydney. As we mentioned in the past, this investigator-initiated trial was inherited upon our acquisition of Send Therapeutics. The original trial was designed with an academic bench rather than one with commercial and regulatory objectives and was statistically powered based on a six-month progression-free survival primary endpoint. This endpoint is unusual in that it has not been previously used as the basis of approval for an anticancer drug.

After the acquisition, we collaborated with the AGITG to modify the trial to ensure it measured clinical endpoints that would best support the next steps in the development of cerdepatide from a regulatory perspective. To that end, the ASCEND protocol was amended to include another cohort of patients, Cohort B, not statistically powered to evaluate an additional cerdepatide dosing regimen. The ASCEND protocol was also amended to capture overall survival outcomes for both cohorts A and B as overall survival is considered by regulatory authorities to be the gold standard endpoint in pancreatic cancer trials. Since the ASCEND protocol was amended following trial initiation, data from Cohort B are being analyzed sequentially following Cohort A data.

Cohort A with 95 patients receiving a single intravenous dose of cerdepatide or placebo in combination with standard of care completed enrollment in 2023. As announced in January, preliminary Cohort A data was presented at the 2025 ASCO GI Symposium which showed a positive trend in overall survival in the cerdepatide plus standard of care chemotherapy group, including four complete responses in this group compared to none in the standard of care plus placebo-treated group. Most recently, preliminary data from Cohort B with 63 patients receiving two intravenous doses of cerdepatide 3.2 mg/kg or placebo, administered four hours apart in combination with standard of care chemotherapy were presented at the ESMO Gastrointestinal Cancers Congress on July 2, 2025.

These data showed a positive trend in progression-free survival, overall survival, and objective response rate in the cerdepatide plus standard of care treatment group compared to the standard of care plus placebo-treated group. Another complete response was also noted in the cerdepatide plus standard of care treated group while none were observed in the standard of care plus placebo group. Additionally, pooled data from both cohorts A and B which was presented at the ESMO Congress on October 20, 2025, further corroborated previous findings and indicated no increased adverse events in the cerdepatide plus standard of care treated group beyond those experienced in the standard of care plus placebo-treated groups.

Final data and conclusions from both cohorts are anticipated for 2026. As we’ve previously announced, we have completed an end of Phase II meeting with the FDA and in conjunction with other correspondence with the agency, have an agreement on the fundamental aspects of an acceptable global Phase III protocol including dose and dosing regimen, blinding, and primary endpoints. Subsequently, we have begun preparation for Phase III trial initiation as contingent upon available capital and anticipated capital acquisition. The BOLTAR trial is our Phase 2a double-blind placebo-controlled multicenter randomized trial in the United States evaluating cerdepatide in combination with standard of care chemotherapy and immunotherapy in first and second-line cholangiocarcinoma on top of standard of care.

Enrollment was completed in the first-line cholangiocarcinoma arm nearly six months ahead of plan, accelerating anticipated top-line data readout to 2025. Based on encouragement from multiple investigators involved in the trial, a second cohort was added evaluating cerdepatide in subjects in second-line cholangiocarcinoma. Although originally planned to recruit 40 patients, enrollment was ultimately capped at approximately 20 patients to allow for quicker data analysis and a more efficient use of our capital. It should be noted that this exploratory trial is not statistically powered. However, the reduced number of patients in the second-line arm should be sufficient to determine if there is a treatment effect.

The SENDFOX trial is a Phase IbIIa open-label trial in the States evaluating cerdepatide in combination with neoadjuvant fulphuranox-based therapies in pancreatic, colon, and appendiceal cancers. In December 2024, the company announced enrollment completion in all three cohorts. This single-center study being conducted at the University of Kansas Cancer Center was designed with a three-cycle run-in period to ensure patients met specific criteria before receiving treatment. Of the 66 patients enrolled, 50 met these criteria and were treated with cerdepatide across three cohorts, including 24 with resectable or borderline resectable pancreatic cancer, 15 with high-grade colon or appendiceal cancers with peritoneal metastases, and 11 with oligometastatic colon cancer.

Preliminary data from the pancreatic cancer cohort presented at the AACR Special Conference in September 2025, showed that the combination of cerdepatide with fulphuranox was safe and feasible. In the ten patients who completed the therapy and underwent surgery, treatment resulted in a 50% R0 resection rate and a 70% pathological partial response alongside promising early survival data, including a 60% two-year overall survival rate. Importantly, the combination therapy appears to transform tumors from immuno-cold to immuno-hot by enhancing immune cell infiltration and increasing markers like PD-1 and PD-L1 which could significantly improve the effect of subsequent immunotherapies. Additional data from the SENDFOX trial are anticipated in the coming months.

The trial is funded by the University of Kansas Cancer Center and Lisata Therapeutics is supplying cerdepatide. Chiso Pharmaceutical, the licensee of cerdepatide in the Greater China territory, is running a parallel development program for cerdepatide in combination with gemcitabine and nab-paclitaxel as a treatment for metastatic pancreatic cancer. Chilu previously reported that they completed enrollment in the study of 90 subjects. However, we still await data from the study to be shared. Also, according to guidance last received from Chilu, data are expected in the next twelve to eighteen months and we anticipate ongoing dialogue to continue related to potential next steps in their development plan.

The IELISTA trial is a Phase 1b2a randomized placebo-controlled three-arm single-blind single-center trial evaluating the safety, early efficacy, pharmacodynamics of cerdepatide in patients with locally advanced non-resectable pancreatic cancer. The trial is being conducted in Australia in collaboration with AstraZeneca, and the funding sponsor WARP nine, combining cerdepatide with the checkpoint inhibitor durvalumab both standard of care gemcitabine and nab-paclitaxel chemotherapy versus cerdepatide in combination with standard of care chemotherapy without durvalumab versus standard of care alone. As recently announced, enrollment in the IELISTA study is complete. An updated interim analysis presented at ESMO GI Congress on July 3, 2025, revealed compelling positive preliminary data for cerdepatide.

These data are consistent with earlier findings from the 2025 ASCO GI meeting further reinforcing cerdepatide’s potential to significantly enhance immunotherapy effectiveness by provoking significant RECIST responses improving overall response and disease control rates. Final data and key findings from this study are anticipated in 2026. A study of cerdepatide in combination with temozolomide in patients with glioblastoma multiforme, or GBM, brain cancer has been initiated with many patients already enrolled and treated. The study is designed as a Phase 2a double-blind placebo-controlled randomized proof of concept study evaluating cerdepatide when added to standard of care temozolomide versus temozolomide alone and matching placebo in subjects with newly diagnosed GBM.

This actively enrolling study is being conducted across multiple sites in Estonia, Latvia, and Lithuania. The study is targeted to enroll 30 patients with a randomization of two to one plus standard of care versus placebo plus standard of care. Enrollment is progressing according to plan and completion of enrollment is expected in 2026. As a reminder, several of the clinical trials I mentioned are investigator-initiated trials, meaning Lisata Therapeutics has limited control over study timelines and expectations may be subject to change. That said, we are incredibly grateful to the investigators and especially to the patients participating in cerdepatide clinical trials around the world.

For more information on each trial, please refer to the appendix section of our corporate presentation on our website. The presentation also includes two slides illustrating the anticipated timelines and execution of key milestones and data readouts. Moving on to exciting business development achievements. As Dave mentioned earlier, Lisata Therapeutics and Catalent entered into a nonexclusive license agreement that grants Catalent global rights to evaluate cerdepatide and its analogs for use as SmartTag payloads across multiple antibody-drug conjugates, or ADCs, designed to address difficult diseases, including advanced solid tumors.

As presented at the World ADC Conference earlier this week, compelling positive data from Catalent’s preclinical study showed both improved tumor-selective penetration and enhanced efficacy, further highlighting cerdepatide’s strong potential to significantly improve the targeting and overall effectiveness of ADCs in advanced solid tumors. Additionally, we’ve established a strategic alliance with GATC Health. This partnership combines Lisata Therapeutics’ drug development expertise with GATC’s AI-powered Multiomics advanced technology platform to accelerate and optimize drug discovery. This includes in silico assessment of cerdepatide for new indications, including some outside of oncology, as well as identifying new chemical entities and/or repurposed existing drugs for diseases with high unmet needs, including non-oncology applications with and without cerdepatide.

The Alliance has already identified a number of development candidates, several of which are anticipated to translate into clinical development during 2026. Further strengthening our intellectual property portfolio, the United States Patent and Trademark Office issued a new composition of matter patent for cerdepatide in July 2025, extending our protection until March 2040 with the potential for further extensions. The patent’s claim covers cerdepatide’s chemical structures, pharmacokinetic properties, methods of manufacturing, and applications for treating solid tumors. With that, I will now turn the call back to Dave.

David Mazzo: Thanks, Kristen. In summary, the past quarter has been active and fruitful as we have both advanced the broad development of cerdepatide while identifying means by which to expand and diversify Lisata Therapeutics’ development pipeline. We continue to evaluate opportunities to bring new products to patients across a variety of cancer and non-cancer indications, and I look forward to sharing our progress on future calls. With that overview, operator, we’re now ready to take questions.

Operator: Thank you. You will then hear an automated message advising that your hand is raised. Each listener will be permitted to ask one question at a time and will return to the queue for any additional questions. Your first question comes from the line of Joe Panccinis with H.C. Wainwright. Your line is open.

Lander Egaña-Gorroño: Hello, everyone. This is Lander on for Joe. Thanks for our questions. So for SENDFOX, when approximately should we expect the next phase to be data cut? And for the GBM trial, could you provide some color on the enrollment status for the target sample size? Thank you.

David Mazzo: Hi, Lander. Thanks for joining and for asking the questions. On SENDFOX, unfortunately, we really cannot give a very precise estimate of when the next data cut will be made available because it’s really under the control of the investigator at the University of Kansas Cancer Center. So we’ll stay close to him. We obviously encourage him to keep things moving along. But the academic world moves at a different pace than the commercial development world. And then, as it relates to, what was your second question?

Lander Egaña-Gorroño: The GBM trial enrollment status.

David Mazzo: As it relates to the GBM trial, as Kristen mentioned, we’re completely on track with that. The target is to enroll 30 patients. I would say that we’re approximately two-thirds of the way through. So things are moving very well according to plan.

Lander Egaña-Gorroño: Perfect. That’s very helpful. Thank you so much.

David Mazzo: Thank you.

Operator: Your next question comes from the line of Robert Sassoon with Water Tower Research. Your line is open.

Robert Sassoon: Thank you. Just a couple of questions. Your cash flow runway to 2027, what is that should be can you sort of run through what I think will include in terms of expenditures going into February 2026?

David Mazzo: Yes, sure. So thanks for the question. James is on the line if we want to go into more detail. But generally speaking, that covers all of the operating expenses for the company, as well as all the expenses to support the ongoing and complete the ongoing clinical trials.

Robert Sassoon: Is there any sort of assumption of a Phase III trial for ASCEND actually incorporated into those assumptions?

David Mazzo: There is not.

Robert Sassoon: Okay. And one more question for me. I mean, you’ve come out with some pretty robust clinical data, a series of them, in the past year. And your share price hasn’t really reacted to it in the way that one would expect for that type of data. What do you think the investors are missing?

David Mazzo: Oh, everything, candidly. I think the problem is a confluence of negative forces that seem to be affecting lots of small-cap companies. But especially frustrating for Lisata Therapeutics where, as you pointed out, we continue to generate positive results across a wide variety of studies, we continue to manage our capital extremely prudently, we continue to make very, I think, astute business deals, and yet the stock doesn’t react. I think that’s partly because the macro environment is not favoring small-cap biotech these days. There aren’t quite a lot of buyers. We’re also stuck in a difficult situation because many of our shareholders treat their holdings in Lisata Therapeutics as a venture capitalist might.

In other words, they’ve made their purchases quite a while ago and they’re holding for the long run, so they don’t trade. And with a limited float like we have on a given day, a very small number of trades could make the market. And that makes our stock somewhat volatile. So I think we are continuing to look for ways to break that paradigm. And our best efforts are to continue to do positive transactions and generate positive data.

But in terms of what the market is missing, I think they’re missing that there’s quite a lot of value in a product that can be used and we’ve demonstrated now that it can be used very broadly across a number of different types of cancers in a variety of different combinations.

Robert Sassoon: Okay, thank you for that answer. That sounds really plausible. I’ll just jump back into the queue.

David Mazzo: Thank you.

Operator: Next question comes from the line of Pete Enderlin with MAZ Partners. Your line is open.

Pete Enderlin: Thank you. Hi, everybody. First, you know, this biotech achievement award, breakthrough award that you got, overall is the word used. Does that mean that you’re the only one that got that? I mean, there might be other lesser awards, but is that basically the only number one award of that type given in for at this time?

David Mazzo: I think we can say that’s the only award with that title or name. Yes, Pete.

Pete Enderlin: Okay. I mean, it seems sort of trivial, the reason I’m asking that is and Dave, you said before that you know, potential licensees or partners want to see more clinical results. And also, of course, we’ve seen a lot of positive results recently, but somebody else said the stock hasn’t responded. And, you know, given the broad application of cerdepatide and maybe some other aspects too in immunotherapy and chemotherapy.

The question that I’m really getting at is wouldn’t it make sense to take a broad brush approach to potential licensees and make a push for that now that you’re starting to gain some momentum and you know, that you could use the ones that you’ve gotten Catalent, and the other for kind of referrals, and therefore you know, kind of beat the bushes for some additional licenses given that for example, Catalent is a nonexclusive license. They would all be exclusive because each one would apply to a particular disease and a particular drug.

And I know you’re probably going to say they cost money, but I have an idea to address that too, which is what about using independent consultants on a contingency fee basis to go out and do that beating the bushes to get licensees I know that’s a lot, but I just wanted to throw it all out there.

David Mazzo: No. No. And I think you’ve done actually, in the form of a question, you’ve actually done a nice job of describing our actual ongoing strategy and execution. That’s exactly what we’re doing. And we don’t need to do that with external consultants. We do that with our internal staff who know the product extremely well. And, you know, so that’s exactly what we’re doing on a regular basis. And we’re building on the momentum of the previous nonexclusive licenses and the interest that was shown in those deals to generate new interest and hopefully build a greater consortium of different licensees.

Pete Enderlin: Okay, great. And just following up on a previous question, the I guess the burn rate looks like it’ll be roughly $3 million per quarter for the next five quarters. Is it going to be fairly level over that period of time?

David Mazzo: Well, let me put it this way. And listen carefully to the way I state this so I’m not misquoting anyone. But I hope not. I actually hope it’s going to go up. And I want it to go up because I want us to be doing more studies which will be generating more data, which is how a company like Lisata Therapeutics ultimately generates value for shareholders. Now of course to do that, we’ll likely have to raise some capital to supplement our current balance sheet. But that would be the plan. Now there are ways for capital to come in through licensing fees, etcetera, that are non-dilutive and of course we’ll give those priority.

Pete Enderlin: Right. Okay, great. Thanks very much.

Operator: Next question comes from the line of Kemp Dolliver with Brookline Capital Markets. Your line is open.

Kemp Dolliver: Great. Thank you. You know, with the final analysis from the ASCEND data coming, you know, relatively soon, could you talk about your thinking for the next steps? Because you know, as everybody on this call knows you need to raise a substantial amount of money to fund the phase three. And you know, there’s some orchestration that goes on to get that done. And so I’d like to know your thinking about you know, the steps in the process you’ll lay out to do so.

David Mazzo: Thanks, Kemp, for the question. And actually the opportunity to be clear on what our plans are. So based upon the data that’s been generated from the Phase 2b trial, we’ve concluded internally that the drug deserves further development and that moving to phase three would be the logical next step. Clearly, in this current financing environment, it’s going to be next to impossible to raise the amount of money necessary to unilaterally fund that phase three in a manner that would not be so overly dilutive to current shareholders as to be distasteful.

So we are working much to Pete’s suggestion, the previous questioner, working to find licensees and partners who will be willing to bear the brunt of that funding or at least contribute in an equal matter to that funding so that we can get that trial done.

In the meantime, we’ve done everything we can and continue to do everything we can internally with existing resources to be prepared to move into Phase III including completing activities on the CMC side that would have us poised for phase three production and NDA validation lot production, having the end of phase 2B meeting with FDA to discuss and agree on a protocol, and preparing similar discussions with other regulatory agencies around the world looking for some consensus on a global protocol. Beginning to have early dialogue with CROs that might be involved in certain areas. And of course, looking for partners and means to fund that trial.

Kemp Dolliver: Okay. And to be clear, this would be along the line. Predominantly on the along the lines of what you know, it would be a pharma partner who would take an indication. This indication may be other indications in order to move the company forward.

David Mazzo: That’s likely the structure of a pharma deal.

David Mazzo: Thank you. Thanks, Kemp. This concludes the question and answer session.

Operator: I will now turn the call back over to Dr. Mazzo for closing remarks.

David Mazzo: Well, again, thank you all for participating in today’s call, and we remain grateful for your continued interest and support in Lisata Therapeutics. Stay well and have a good evening.

Operator: Ladies and gentlemen, that concludes today’s call. Thank you all for joining. You may now disconnect.